To the Editor Phillips et al1 have reported a phase 2 randomized clinical trial assessing the role of stereotactic body radiotherapy in men with up to 3 nodal and/or bone metastases after primary treatment for prostate cancer. The authors should be commended for this trial, which showed higher efficacy of metastasis-directed therapy (MDT) without concomitant systemic treatment compared with observation with regard to 6-month progression-free survival. However, unfortunately, this trial fails to shed light on the correct management of oligorecurrent prostate cancer for the following reasons.